Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) announced that CEO Vicente Anido, Jr., Ph.D., will speak at the Raymond James Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. ET. The discussion will cover an Aerie overview, business updates, sales figures, and the introduction of AR-6121, a new pipeline opportunity. Dr. Anido will also discuss the progress of Rhopressa development in Japan. The session will be webcast live on Aerie's website, with a replay available for 10 business days.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. Eastern Time. In addition to providing an Aerie overview and business update, Dr. Anido will discuss updated sales out numbers, introduce AR-6121, Aerie’s new pipeline opportunity, and discuss progress in the Rhopressa^® development program in Japan.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of the fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005349/en/

FAQ

What is Aerie Pharmaceuticals presenting at the Raymond James Human Health Innovation Conference?

Aerie Pharmaceuticals CEO Vicente Anido will present updates on the company, including sales figures and the introduction of AR-6121.

When will Aerie Pharmaceuticals present at the Raymond James Conference?

The presentation will take place on June 22, 2021, at 1:20 p.m. Eastern Time.

How can I watch Aerie Pharmaceuticals' presentation from the conference?

The presentation will be webcast live on Aerie's website.

What new pipeline opportunity will Aerie Pharmaceuticals introduce?

Aerie will introduce AR-6121 during the presentation.

What is the focus of Aerie Pharmaceuticals?

Aerie focuses on developing therapies for open-angle glaucoma, ocular surface diseases, and retinal diseases.

What updates will Aerie Pharmaceuticals provide regarding Rhopressa?

Dr. Anido will discuss the progress of the Rhopressa development program in Japan.